Stockwatch: An Earnings Season Renaissance Fades
Executive Summary
Big pharma companies like Novartis, Merck, Bristol-Myers Squibb and Eli Lilly tried to restore a semblance of positivity to third-quarter earnings season last week but a counter-current of detail in the results of Vertex, Amgen and Biogen gave other ideas.
You may also be interested in...
Stockwatch: 2017, Year Of The Dog
News in the life sciences sector over the holiday period was peppered with clinical and regulatory failures at Acadia, Anthera, Opko and Cempra, and a drug pricing controversy from Biogen. Following underperformance in 2016 and with that sort of run-up, 2017 already looks likely to be another lost one.
Novo Nordisk Shakes Up R&D Strategy To Cope With US Pricing Pressures
Increasing competition and pricing pressures in the US, have led Novo Nordisk to halve its profit growth expectations for 2017. In response, the diabetes drug developer plans to double-down on R&D efforts, expand into new therapy areas and seek external deals for early-stage assets to bulk up its pipeline.
Amgen’s Biggest Seller Enbrel Hit By Pricing Pressures, Competition
Amgen signaled future declines in revenue for its top-selling product Enbrel during its third quarter conference call as payer pressure on drug pricing and competition mounts.